Potential impact of rapid diagnostic tests on improving antimicrobial use

Annals of the New York Academy of Sciences

Volumn 1213, Issue 1, 2010, Pages 70-80

  Tenover, Fred C ^a  

^a CEPHEID   (United States)

Author keywords

Antimicrobial agent; Molecular diagnostics; Nucleic acid amplification; PCR; Susceptibility testing

Indexed keywords

ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE; COTRIMOXAZOLE; OXACILLIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM DETECTION; CLINICAL DECISION MAKING; DIAGNOSTIC TEST; DRUG USE; EARLY DIAGNOSIS; HUMAN; INFECTION; MOLECULAR DIAGNOSIS; NONHUMAN; NUCLEIC ACID AMPLIFICATION; RESPIRATORY TRACT INFECTION; SEPSIS; SEXUALLY TRANSMITTED DISEASE;

BACTERIA (MICROORGANISMS);

EID: 78650406839     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05827.x     Document Type: Article

References (78)

1. Spellberg, B. et al 2008. The epidemic of antibioticâ-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin. Infect. Dis. 46: 155-164.
2. Tenover, F.C. & J. Hindler 2010. Reporting antimicrobial susceptibility testing results. In Antibiogram. P. Courvalin, R. LeClercq & L.B. Rice, Eds.: 89-98. ASM Press. Washington, DC
3. Holland, T.L., C.W. Woods & M. Joyce 2009. Antibacterial susceptibility testing in the clinical laboratory. Infect. Dis. Clin. North Am. 23: 757-790.
4. American Thoracic Society. 2005. Guidelines for the management of adults with hospitalâ-acquired, ventilatorâ-associated, and healthcareâ-associated pneumonia. Am. J. Respir. Crit. Care Med. 171: 388-416.
5. Kollef, M.H. 2008. Broadâ-spectrum antimicrobials and the treatment of serious bacterial infections: getting it right up front. Clin. Infect. Dis. 47(Suppl. 1): S3-S13.
6. Morrell, M.R., S.T. Micek & M.H. Kollef 2009. The management of severe sepsis and septic shock. Infect. Dis. Clin. North Am. 23: 485-501.
7. Doern, G.V. et al 1994. Clinical impact of rapid in vitro susceptibility testing and bacterial identification. J. Clin. Microbiol. 32: 1757-1762.
8. Ling, T.K., Z.K. Liu & A.F. Cheng 2003. Evaluation of the VITEK 2 system for rapid direct identification and susceptibility testing of gramâ-negative bacilli from positive blood cultures. J. Clin. Microbiol. 41: 4705-4707.
9. Kerremans, J.J. et al 2008. Rapid identification and antimicrobial susceptibility testing reduce antibiotic use and accelerate pathogenâ-directed antibiotic use. J. Antimicrob. Chemother. 61: 428-435.
10. Mirrett, S. & L.B. Reller 1979. Comparison of direct and standard antimicrobial disk susceptibility testing for bacteria isolated from blood. J. Clin. Microbiol. 10: 482-487.
11. Jorgensen, J.H. et al 2000. Rapid automated antimicrobial susceptibility testing of Streptococcus pneumoniae by use of the bioMerieux VITEK 2. J. Clin. Microbiol. 38: 2814-2818.
12. Mermel, L.A. et al 2009. Clinical practice guidelines for the diagnosis and management of intravascular catheterâ-related infection: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 49: 1-45.
13. Woodhead, M. et al 2005. Guidelines for the management of adult lower respiratory tract infections. Eur. Respir. J. 26: 1138-1180.
14. Wolk, D.M. et al 2009. Rapid detection of Staphylococcus aureus and methicillinâ-resistant S. aureus (MRSA) in wound specimens and blood cultures: multicenter preclinical evaluation of the Cepheid Xpert MRSA/SA skin and soft tissue and blood culture assays. J. Clin. Microbiol. 47: 823-826.
15. Christner, M. et al 2010. Rapid identification of bacteria from positive blood culture bottles by use of matrixâ-assisted laser desorptionâ-ionization time of flight mass spectrometry fingerprinting. J. Clin. Microbiol. 48: 1584-1591.
16. Ferreira, L. et al 2010. Direct identification of urinary tract pathogens from urine samples by matrixâ-assisted laser desorption ionizationâ-time of flight mass spectrometry. J. Clin. Microbiol. 48: 2110-2115.
17. Hindler, J.F. & J. Stelling 2007. Analysis and presentation of cumulative antibiograms: a new consensus guideline from the Clinical and Laboratory Standards Institute. Clin. Infect. Dis. 44: 867-873.
18. Parta, M. et al 2009. Identification of methicillinâ-resistant or methicillinâ-susceptible Staphylococcus aureus in blood cultures and wound swabs by GeneXpert. J. Clin. Microbiol. 47: 1609-1610.
19. Stamper, P.D. et al 2007. Clinical validation of the molecular BD GeneOhm StaphSR assay for direct detection of Staphylococcus aureus and methicillinâ-resistant Staphylococcus aureus in positive blood cultures. J. Clin. Microbiol. 45: 2191-2196.
20. Forrest, G.N. et al 2006. Impact of rapid in situ hybridization testing on coagulaseâ-negative staphylococci positive blood cultures. J. Antimicrob. Chemother. 58: 154-158.
21. Small, P.M. & H.F. Chambers 1990. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob. Agents Chemother. 34: 1227-1231.
22. Tenover, F.C. & R.C. Moellering Jr. 2007. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin. Infect. Dis. 44: 1208-1215.
23. Reik, R. et al 2008. The burden of vancomycinâ-resistant enterococcal infections in US hospitals, 2003 to 2004. Diagn. Microbiol. Infect. Dis. 62: 81-85.
24. Forrest, G.N. et al 2008. Peptide nucleic acid fluorescent in situ hybridization for hospitalâ-acquired enterococcal bacteremia: delivering earlier effective antimicrobial therapy. Antimicrob. Agents Chemother. 52: 3558-3563.
25. Morgan, M. et al 2010. Multicenter evaluation of a new shortened peptide nucleic acid fluorescence in situ hybridization procedure for species identification of select Gramâ-negative bacilli from blood cultures. J. Clin. Microbiol. 48: 2268-2270.
26. Pappas, P.G. et al 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48: 503-535.
27. Forrest, G.N. et al 2006. Peptide nucleic acid fluorescence in situ hybridizationâ-based identification of Candida albicans and its impact on mortality and antifungal therapy costs. J. Clin. Microbiol. 44: 3381-3383.
28. Goldenberger, D. et al 1997. Molecular diagnosis of bacterial endocarditis by broadâ-range PCR amplification and direct sequencing. J. Clin. Microbiol. 35: 2733-2739.
29. Relman, D.A. et al 1990. The agent of bacillary angiomatosis. An approach to the identification of uncultured pathogens. N. Engl. J. Med. 323: 1573-1580.
30. Peters, R.P. et al 2004. Detection of bacterial DNA in blood samples from febrile patients: underestimated infection or emerging contamination? FEMS Immunol. Med. Microbiol. 42: 249-253.
31. Corless, C.E. et al 2000. Contamination and sensitivity issues with a realâ-time universal 16S rRNA PCR. J. Clin. Microbiol. 38: 1747-1752.
32. Rand, K.H. & H. Houck 1990. Taq polymerase contains bacterial DNA of unknown origin. Mol. Cell Probes 4: 445-450.
33. Westh, H. et al 2009. Multiplex realâ-time PCR and blood culture for identification of bloodstream pathogens in patients with suspected sepsis. Clin. Microbiol. Infect. 15: 544-551.
34. von Lilienfeldâ-Toal, M. et al 2009. Utility of a commercially available multiplex realâ-time PCR assay to detect bacterial and fungal pathogens in febrile neutropenia. J. Clin. Microbiol. 47: 2405-2410.
35. Heyrend, C. et al 2010. Rapid identification of sepsis pathogens using realâ-time nested multiplex PCR. Proceedings of the Presented at 110th General Meeting of the American Society for Microbiology Abstract Câ-1109, San Diego, CA, May 23-27.
36. McCaig, L.F., R.E. Besser & J.M. Hughes 2002. Trends in antimicrobial prescribing rates for children and adolescents. JAMA 287: 3096-3102.
37. Gonzales, R. et al 2001. Excessive antibiotic use for acute respiratory infections in the United States. Clin. Infect. Dis. 33: 757-762.
38. Snow, V., C. Motturâ-Pilson & R. Gonzales 2001. Principles of appropriate antibiotic use for treatment of nonspecific upper respiratory tract infections in adults. Ann. Intern. Med. 134: 487-489.
39. Gonzales, R. et al 2001. Principles of appropriate antibiotic use for treatment of uncomplicated acute bronchitis: background. Ann. Intern. Med. 134: 521-529.
40. Bauchner, H., S.I. Pelton & J.O. Klein 1999. Parents, physicians, and antibiotic use. Pediatrics 103: 395-401.
41. Barden, L.S. et al 1998. Current attitudes regarding use of antimicrobial agents: results from physician's and parents' focus group discussions. Clin. Pediatr. (Phila) 37: 665-671.
42. Mandell, L.A. et al 2007. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of communityâ-acquired pneumonia in adults. Clin. Infect. Dis. 44(Suppl. 2): S27-S72.
43. Bouza, E. et al 2007. Direct Eâ-test (AB Biodisk) of respiratory samples improves antimicrobial use in ventilatorâ-associated pneumonia. Clin. Infect. Dis. 44: 382-387.
44. Fukushima, K.Y. et al 2008. Rapid identification of penicillin and macrolide resistance genes and simultaneous quantification of Streptococcus pneumoniae in purulent sputum samples by use of a novel realâ-time multiplex PCR assay. J. Clin. Microbiol. 46: 2384-2388.
45. Clinical and Laboratory Standards Institute. 2010. Performance Standards for Antimicrobial Susceptibility Testing; Twentieth Informational Supplement; M100â-S20. June 2010 Update. Clinical and Laboratory Standards Institute. Wayne, PA
46. Bartlett, J.G. 2004. Diagnostic test for etiologic agents of communityâ-acquired pneumonia. Infect. Dis. Clin. North Am. 18: 809-827.
47. Murdoch, D.R. et al 2009. Breathing new life into pneumonia diagnostics. J. Clin. Microbiol. 47: 3405-3408.
48. Berton, D.C. et al 2008. Quantitative versus qualitative cultures of respiratory secretions for clinical outcomes in patients with ventilatorâ-associated pneumonia CD006482. Cochrane Database Syst. Review 4.
49. World Health Organization. 2008. Global Tuberculosis Control: Surveillance, Planning, Financing. Global report 2009 update, Vol. 2010. World Health Organization Geneva.
50. Centers for Disease Control and Prevention. 2009. Updated guidelines for the use of nucleic acid amplification tests in the diagnosis of tuberculosis. MMWR Morb. Mortal. Wkly. Rep. 58: 7-10.
51. Laraque, F. et al 2009. Performance of nucleic acid amplification tests for diagnosis of tuberculosis in a large urban setting. Clin. Infect. Dis. 49: 46-54.
52. Syre, H. et al 2009. Direct detection of mycobacterial species in pulmonary specimens by two rapid amplification tests, the Genâ-probe amplified Mycobacterium tuberculosis direct test and the genotype mycobacteria direct test. J. Clin. Microbiol. 47: 3635-3639.
53. Akpaka, P.E. et al 2008. Evaluation of methods for rapid detection of resistance to isoniazid and rifampin in Mycobacterium tuberculosis isolates collected in the Caribbean. J. Clin. Microbiol. 46: 3426-3428.
54. Helb, D. et al 2010. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of onâ-demand, nearâ-patient technology. J. Clin. Microbiol. 48: 229-237.
55. Blakemore, R. et al 2010. Evaluation of the analytical performance of the Xpert(R) MTB/RIF assay. J. Clin. Microbiol 48: 2495-2501.
56. Boehme, C.C. et al 2010. Rapid molecular detection of tuberculosis and rifampin resistance. N. Engl. J. Med. 363: 1005-1015.
57. Centers for Disease Control and Prevention. 2007. Extensively drugâ-resistant tuberculosis-United States, 1993-2006. MMWR Morb. Mortal. Wkly. Rep. 56: 250-253.
58. Centers for Disease Control and Prevention. 2009. Trends in tuberculosis-United States, 2008. MMWR Morb. Mortal. Wkly. Rep. 58: 249-253.
59. Evans, J. et al 2009. Rapid genotypic assays to identify drugâ-resistant Mycobacterium tuberculosis in South Africa. J. Antimicrob. Chemother. 63: 11-16.
60. Arnold, C. et al 2005. Singleâ-nucleotide polymorphismâ-based differentiation and drug resistance detection in Mycobacterium tuberculosis from isolates or directly from sputum. Clin. Microbiol. Infect. 11: 122-130.
61. Zhao, J.R. et al 2005. Development of a pyrosequencing approach for rapid screening of rifampin, isoniazid and ethambutolâ-resistant Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 9: 328-332.
62. Bravo, L.T. et al 2009. Pyrosequencing for rapid detection of Mycobacterium tuberculosis resistance to rifampin, isoniazid, and fluoroquinolones. J. Clin. Microbiol. 47: 3985-3990.
63. Garzaâ-Gonzalez, E. et al 2009. A pyrosequencing method for molecular monitoring of regions in the inhA, ahpC and rpoB genes of Mycobacterium tuberculosis. Clin. Microbiol. Infect. 16: 607-612.
64. Motiwala, A.S. et al Mutations in extensively drugâ-resistant Mycobacterium tuberculosis that do not code for known drugâ-resistance mechanisms. J. Infect. Dis. 201: 881-888.
65. Klevens, R.M. et al 2006. Communityâ-associated methicillinâ-resistant Staphylococcus aureus and healthcare risk factors. Emerg. Infect. Dis. 12: 1991-1993.
66. Clinical and Laboratory Standards Institute. 2010. Surveillance for Methicillinâ-Resistant Staphylococcus aureus: Principles, Practices, and Challenges; A Report Xâ-07R. Clinical and Laboratory Standards Institute. Wayne, PA
67. Robicsek, A. et al 2008. Universal surveillance for methicillinâ-resistant Staphylococcus aureus in 3 affiliated hospitals. Ann. Intern. Med. 148: 409-418.
68. Bode, L.G. et al 2010. Preventing surgicalâ-site infections in nasal carriers of Staphylococcus aureus. N. Engl. J. Med. 362: 9-17.
69. Simor, A.E. et al 2007. Mupirocinâ-resistant, methicillinâ-resistant Staphylococcus aureus strains in Canadian hospitals. Antimicrob. Agents. Chemother. 51: 3880-3886.
70. Centers for Disease Control and Prevention. 2010, posting date. Sexually Transmitted Diseases Surveillance, 2008. (accessed October 20, 2010).
71. Centers for Disease Control and Prevention. 2007. Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR Morb. Mortal. Wkly. Rep. 56: 332-336.
72. Martin, I.M. et al 2005. Changing epidemiologic profile of quinoloneâ-resistant Neisseria gonorrhoeae in London. J. Infect. Dis. 192: 1191-1195.
73. Vernelâ-Pauillac, F. et al 2009. Quinolone resistance in Neisseria gonorrhoeae: rapid genotyping of quinolone resistanceâ-determining regions in gyrA and parC genes by melting curve analysis predicts susceptibility. Antimicrob. Agents Chemother. 53: 1264-1267.
74. Vernelâ-Pauillac, F. & F. Merien 2006. A novel realâ-time duplex PCR assay for detecting penA and ponA genotypes in Neisseria gonorrhoeae: comparison with phenotypes determined by the Eâ-test. Clin. Chem. 52: 2294-2296.
75. Paule, S.M. et al 2007. Performance of the BD GeneOhm methicillinâ-resistant Staphylococcus aureus test before and during highâ-volume clinical use. J. Clin. Microbiol. 45: 2993-2998.
76. Wolk, D.M. et al 2009. Multicenter evaluation of the Cepheid Xpert methicillinâ-resistant Staphylococcus aureus (MRSA) test as a rapid screening method for detection of MRSA in nares. J. Clin. Microbiol. 47: 758-764.
77. Peterson, L.R. et al Multicenter evaluation of the LightCycler methicillinâ-resistant Staphylococcus aureus (MRSA) advanced test as a rapid method for detection of MRSA in nasal surveillance swabs. J. Clin. Microbiol. 48: 1661-1666.
78. Deiman, B. et al 2008. Efficient amplification with NASBA of hepatitis B virus, herpes simplex virus and methicillin resistant Staphylococcus aureus DNA. J. Virol. Methods. 151: 283-293.